Related Experiment Video
Updated: Aug 16, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
[Renin-angiotensin system in diabetic nephropathy]
1Jefe del Servicio de Nefrología, Hospital General Universitario Gregorio Marañón, Madrid. jluno.hgugm@salud.madrid.org
Summary
Blocking the renin-angiotensin system (RAS) can prevent diabetic nephropathy progression. Early detection of microalbuminuria and strict blood pressure control are crucial for managing diabetes and reducing cardiovascular risk.
Area of Science:
- Nephrology
- Endocrinology
- Cardiovascular Medicine
Background:
- Diabetic nephropathy is a major complication of diabetes.
- The renin-angiotensin system (RAS) plays a key role in its development and progression.
- RAS blockers have shown promise in preventing kidney damage in diabetic patients.
Purpose of the Study:
- To emphasize the importance of RAS in diabetic nephropathy.
- To highlight the need for early detection and preventive programs for microalbuminuria.
- To underscore the role of RAS blockers in preventing diabetic nephropathy progression.
Main Methods:
- Review of current evidence on RAS and diabetic nephropathy.
- Emphasis on early detection of microalbuminuria.
- Importance of controlling blood pressure, glucose, and lipids.
Main Results:
- RAS blockade can prevent the development and progression of diabetic nephropathy.
- RAS blockers are effective even with normal blood pressure in patients with microalbuminuria.
- Strict blood pressure control is essential for preventing nephropathy and cardiovascular risk.
Conclusions:
- RAS blockade is a vital strategy for managing diabetic nephropathy.
- Early detection of microalbuminuria and comprehensive risk factor control are critical.
- Preventive programs targeting RAS are needed to reduce the burden of diabetic kidney disease.
Related Concept Videos
01:28Diabetic Nephropathy
Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:29Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...